Management of Dyslipidaemias
Cardiovascular disease remains a leading cause of death worldwide, with low-density lipoproteins and other atherogenic lipoproteins, such as lipoprotein remnants, playing a key role in the development of atherosclerosis. Beyond LDL cholesterol, the identification of biological, environmental, and ge...
Saved in:
| Format: | Online |
|---|---|
| Language: | English |
| Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2026
|
| Subjects: | |
| Online Access: | ONIX_20260416T142754_9783725856237_12 |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1869523249492131840 |
|---|---|
| collection | Directory of Open Access Books |
| description | Cardiovascular disease remains a leading cause of death worldwide, with low-density lipoproteins and other atherogenic lipoproteins, such as lipoprotein remnants, playing a key role in the development of atherosclerosis. Beyond LDL cholesterol, the identification of biological, environmental, and genetic markers associated with remnant metabolism has improved cardiovascular risk prediction and informed treatment strategies. This Reprint examines rare and severe lipid disorders, including homozygous familial hypercholesterolemia, refractory hypercholesterolemia, and severe hypertriglyceridemia, which continue to present major therapeutic challenges despite maximally tolerated lipid-lowering therapies. It also highlights the rapid development of novel inhibitors such as PCSK9, ANGPTL3, and APOC3, as well as emerging therapies derived from new mechanistic pathways. In addition, the link between metabolic conditions such as non-alcoholic steatohepatitis and cardiovascular events is explored. Collectively, the articles in this Reprint provide a comprehensive and up-to-date overview of current advances, ongoing challenges, and future perspectives in lipid modification and cardiovascular risk management. |
| format | Online |
| id | doab-20.500.12854ir-174907 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2026 |
| publishDateRange | 2026 |
| publishDateSort | 2026 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1749072026-04-16T17:18:02Z Management of Dyslipidaemias Gaudet, Daniel Khoury, Etienne Cardiovascular disease Dyslipidemia Lipoprotein remnant Emerging lipid-lowering therapies Rare and severe causes of atherogenic lipid disorders Cardiovascular risk-related biomarkers Drug safety and efficacy thema EDItEUR::M Medicine and Nursing Cardiovascular disease remains a leading cause of death worldwide, with low-density lipoproteins and other atherogenic lipoproteins, such as lipoprotein remnants, playing a key role in the development of atherosclerosis. Beyond LDL cholesterol, the identification of biological, environmental, and genetic markers associated with remnant metabolism has improved cardiovascular risk prediction and informed treatment strategies. This Reprint examines rare and severe lipid disorders, including homozygous familial hypercholesterolemia, refractory hypercholesterolemia, and severe hypertriglyceridemia, which continue to present major therapeutic challenges despite maximally tolerated lipid-lowering therapies. It also highlights the rapid development of novel inhibitors such as PCSK9, ANGPTL3, and APOC3, as well as emerging therapies derived from new mechanistic pathways. In addition, the link between metabolic conditions such as non-alcoholic steatohepatitis and cardiovascular events is explored. Collectively, the articles in this Reprint provide a comprehensive and up-to-date overview of current advances, ongoing challenges, and future perspectives in lipid modification and cardiovascular risk management. 2026-04-16T17:17:55Z 2026-04-16T17:17:55Z 2025 book ONIX_20260416T142754_9783725856237_12 9783725856237 9783725856244 https://directory.doabooks.org/handle/20.500.12854/174907 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/ https://mdpi.com/books/pdfview/book/11789 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-7258-5624-4 10.3390/books978-3-7258-5624-4 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783725856237 9783725856244 150 CH open access |
| spellingShingle | Cardiovascular disease Dyslipidemia Lipoprotein remnant Emerging lipid-lowering therapies Rare and severe causes of atherogenic lipid disorders Cardiovascular risk-related biomarkers Drug safety and efficacy thema EDItEUR::M Medicine and Nursing Management of Dyslipidaemias |
| title | Management of Dyslipidaemias |
| title_full | Management of Dyslipidaemias |
| title_fullStr | Management of Dyslipidaemias |
| title_full_unstemmed | Management of Dyslipidaemias |
| title_short | Management of Dyslipidaemias |
| title_sort | management of dyslipidaemias |
| topic | Cardiovascular disease Dyslipidemia Lipoprotein remnant Emerging lipid-lowering therapies Rare and severe causes of atherogenic lipid disorders Cardiovascular risk-related biomarkers Drug safety and efficacy thema EDItEUR::M Medicine and Nursing |
| topic_facet | Cardiovascular disease Dyslipidemia Lipoprotein remnant Emerging lipid-lowering therapies Rare and severe causes of atherogenic lipid disorders Cardiovascular risk-related biomarkers Drug safety and efficacy thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20260416T142754_9783725856237_12 |